01/10/23 7:55 AMNasdaq : VCEL earningsVericel Announces Preliminary Fourth-Quarter and Full-Year 2022 Financial Results and Accelerated Launch Timeline for MACI Arthroscopic ProgramFull-Year Total Revenue Expected to be Approximately $164 to $165 Million MACI Full-Year Revenue Expected to be at the High End of Guidance Range, with Fourth Quarter Revenue Growth of Approximately 24% MACI Arthroscopic Commercial Launch Now Planned for 2024 CAMBRIDGE, Mass., Jan. 10, 2023RHEA-AIpositive
01/05/23 9:00 AMNasdaq : VCEL managementKytopen Appoints Paul K. Wotton, Ph.D. to Chair of Board of DirectorsFollowing the appointment of Dr. Wotton, the Board will comprise of five directors including Ann DeWitt, Adam Wieschhaus, Cullen Buie, and Paulo Garcia. Dr. Wotton serves on the Board of Directors of Vericel Corporation and Cynata Therapeutics and is a Founder of Avenge Bio. Dr. Wotton was recently named as a“ Top 100 Innovation CEO” by World Biz Magazine and won the...RHEA-AIneutral
01/04/23 8:34 AMNasdaq : VCEL conferencesVericel to Present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO will present at the 41 st Annual J.P. Morgan Healthcare Conference.RHEA-AIneutral
12/29/22 1:45 PMNasdaq : VCEL fda approvalVericel Announces FDA Approval of NexoBrid for the Treatment of Severe Thermal Burns in AdultsPotential to become the new standard of care for eschar removal in patients with deep partial- and/or full- thickness thermal burns Label supported by robust clinical data demonstrating significantly higher incidence of complete eschar removal in patients treated with NexoBrid compared to placeboRHEA-AIpositive
11/10/22 9:00 AMNasdaq : VCEL conferencesVericel to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health & Service Forum and the Stephens Annual Investment ConferenceVericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Company leadership will present at the upcoming Canaccord Genuity MedTech, Diagnostics, and DigitalRHEA-AIneutral
11/09/22 7:55 AMNasdaq : VCEL earningsVericel Reports Third Quarter 2022 Financial ResultsVericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burnRHEA-AIneutral
10/26/22 8:30 AMNasdaq : VCEL conferencesearningsVericel to Report Third-Quarter 2022 Financial Results on November 9, 2022Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its third-quarter 2022 financial results on Wednesday, November 9, 2022. Vericel’sRHEA-AIneutral
09/22/22 8:30 AMNasdaq : VCEL conferencesVericel to Present at the Ladenburg Thalmann Healthcare ConferenceVericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Chief Financial Officer Joe Mara will present at the upcoming Ladenburg Thalmann Healthcare Conference.RHEA-AIneutral
09/06/22 8:30 AMNasdaq : VCEL conferencesVericel to Present at the Morgan Stanley Global Healthcare and H.C. Wainwright Global Investment ConferencesVericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Company leadership will present at the upcoming Morgan Stanley and H.C. Wainwright investorRHEA-AIneutral
08/03/22 7:55 AMNasdaq : VCEL earningsVericel Reports Second Quarter 2022 Financial ResultsVericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn careRHEA-AIneutral